Lokelma approved in the EU for the treatment of adults with hyperkalaemia

Patients will benefit from Lokelma’s rapid reduction and sustained control of potassium levels in the blood4,5AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.1,2,3,4 Lokelma is a highly-selective, oral potassium-removing agent. The approval is supported by data from three double-blind,